Ulacamten
Small molecule
Also known as CK-4021586
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
AMBER-HFpEF NCT06793371 · Heart Failure with Preserved Ejection Fraction Registry: NCT06793371 | 2 | Incidence of early drug discontinuation (12 weeks); Incidence of LVEF < 40% (12 weeks); Incidence of AEs (12 weeks) 2026-09 | In progress: primary completion was expected 1 Sept 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Cardiac myosin (inhibitor) drugs
Aficamten, Mavacamten, HRS-1893, Delocamten. Compare all 5 Cardiac myosin (inhibitor) drugs
4 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Heart Failure with Preserved Ejection Fraction: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ulacamten: this drug | Phase 2 | Small molecule | Cardiac myosin (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Aficamten (Myqorzo) | Approved(overall) | Small molecule | Cardiac myosin (inhibitor) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Mavacamten (Camzyos) | Approved(overall) | Small molecule | Cardiac myosin (inhibitor) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| HRS-1893 | Phase 3(overall) | Undisclosed | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Semaglutide (Wegovy) | Phase 3 | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Delocamten | Phase 2 | Small molecule | Cardiac myosin (inhibitor) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.